Cti Bio Pharma
Biotechnology, 3101 Western Ave Ste 800, Seattle, Washington, 98121, United States, 51-200 Employees
Phone Number: 12*********
Who is CTI BIOPHARMA
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benef...
Read More
-
Headquarters: 3101 Western Ave Ste 800, Seattle, Washington, 98121, United States
-
Date Founded: 1992
-
Employees: 51-200
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
-
CEO:
Laurie Liming
Email
Phone
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from CTI BIOPHARMA
CTI BioPharma Org Chart and Mapping
Shantha Tyavanagimatt
Senior Vice President, Global Pharmaceutical Operations (Cmc) and Early Development
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding CTI BioPharma
Answer: CTI BioPharma's headquarters are located at 3101 Western Ave Ste 800, Seattle, Washington, 98121, United States
Answer: CTI BioPharma's phone number is 12*********
Answer: CTI BioPharma's official website is https://ctibiopharma.com
Answer: CTI BioPharma's revenue is $1 Million to $5 Million
Answer: CTI BioPharma's SIC: 2834
Answer: CTI BioPharma's NAICS: 325412
Answer: CTI BioPharma has 51-200 employees
Answer: CTI BioPharma is in Biotechnology
Answer: CTI BioPharma contact info: Phone number: 12********* Website: https://ctibiopharma.com
Answer: We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 10^9/L. This indication is approved under FDA accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO^TM is a trademark of CTI BioPharma Corp.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Powered by
Sign in to CIENCE GO Data to uncover contact details
Free credits every month